News

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer


Date: 27/07/2015


Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans?

Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced three days ago that it received European market approval for its rival therapy… bittersweet news for Sanofi.

For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019